Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 646 to 660 of 1334 results for long term conditions

  1. Robot-assisted kidney transplant (HTG468)

    Evidence-based recommendations on robot-assisted kidney transplant in adults. This involves the surgeon using a robot to help with a kidney transplant.

  2. Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)

    Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and imatinib (Glivec) for untreated chronic myeloid leukaemia in adults.

  3. Endoscopic balloon dilation for subglottic or tracheal stenosis (HTG614)

    Evidence-based recommendations on intramedullary distraction for lower limb lengthening in children, young people and adults. This involves surgically inserting a metal lengthening device in the shorter leg.

  4. Lateral elbow resurfacing for arthritis (HTG591)

    Evidence-based recommendations on lateral elbow resurfacing for arthritis. This involves inserting an implant into the 2 bones that form the joint at the outer part of the elbow, under general anaesthetic.

  5. Focal therapy using high-intensity focused ultrasound for localised prostate cancer (HTG667)

    Evidence-based recommendations on focal therapy using high-intensity focused ultrasound for localised prostate cancer. This involves using high-intensity focused ultrasound to heat up and destroy only the areas of the prostate with cancer (focal therapy). The aim is to destroy the cancer while reducing damage to healthy prostate tissue.

  6. Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer (HTG522)

    Evidence-based recommendations on transurethral laser ablation for recurrent non-muscle-invasive bladder cancer in adults. This involves using a laser inserted into the bladder to destroy the cancer cells.

  7. Reinforcement of a permanent stoma with a synthetic or biological mesh to prevent a parastomal hernia (HTG519)

    Evidence-based recommendations on reinforcement of a permanent stoma with a synthetic or biological mesh to prevent a parastomal hernia. This involves inserting a piece of mesh to strengthen the abdominal wall.

  8. Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia in adults.

  9. Maternal and child nutrition: nutrition and weight management in pregnancy, and nutrition in children up to 5 years (NG247)

    This guideline covers nutrition and weight management in pregnancy for anyone who may become pregnant, is planning to become pregnant or is already pregnant, and nutrition in children up to 5 years. Care of babies and children born preterm or with low birth weight is not covered. The guideline does not give detailed advice on what constitutes a healthy diet.

  10. Harmful sexual behaviour among children and young people (NG55)

    This guideline covers children and young people who display harmful sexual behaviour, including those on remand or serving community or custodial sentences. It aims to ensure these problems don’t escalate and possibly lead to them being charged with a sexual offence. It also aims to ensure no-one is unnecessarily referred to specialist services.

  11. Robot-assisted surgery for soft tissue procedures: early value assessment (HTG742)

    Early value assessment (EVA) guidance on robot-assisted surgery for soft tissue procedures.

  12. Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor (TA1062)

    Evidence-based recommendations on erdafitinib (Balversa) for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor in adults.

  13. Workplace health for employees with disabilities and long-term conditions

    Discontinued Reference number: GID-PHG58

  14. Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)

    Evidence-based recommendations on continuous subcutaneous insulin infusion (insulin pump therapy) for treating type 1 diabetes in adults and children.

  15. Benralizumab for treating severe eosinophilic asthma (TA565)

    Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.